PTC THERAPEUTICS, INC.

PTCT 10-K · FY 2025
API behind this page

PTCT FY 2025 request

Playground key active
Request URL /api/financials?ticker=PTCT&year=2025&quarter=4&full_year_mode=true
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric FY 2025 FY 2024 YoY
Revenue 1,730,655 806,780 +114.5%
Show Product Lines breakouts
All other products 37,264 36,946 +0.9%
All other products · Non Us 37,264 36,946 +0.9%
Collaboration and license revenue 998,357 304 +328306.9%
Collaboration and license revenue · Novartis 1 — —
Emflaza 146,361 207,215 -29.4%
Emflaza · US 146,361 207,215 -29.4%
Product 586,703 582,145 +0.8%
Product · Non Us 334,518 374,930 -10.8%
Product · US 252,185 207,215 +21.7%
Royalty 244,224 203,864 +19.8%
Royalty · Collaborative Arrangement 244.2 203.9 +19.8%
Sephience 111,153 — —
Sephience · Non Us 16,108 — —
Sephience · US 95,045 — —
Translarna 235,299 321,071 -26.7%
Translarna -98,629 18,806 -624.5%
Translarna · Non Us 235,299 321,071 -26.7%
Translarna · Sales Returns And Allowances 98.6 — —
Upstaza/Kebilidi 56,626 16,913 +234.8%
Upstaza/Kebilidi · Non Us 45,847 16,913 +171.1%
Upstaza/Kebilidi · US 10,779 — —
Show Business Segments breakouts
Life Science · Operating Segments 1,730,655 806,780 +114.5%
Show Geography breakouts
All other countries 168,412 197,472 -14.7%
BR 65,661 72,081 -8.9%
Non Us 235,888 393,736 -40.1%
RU 100,445 105,377 -4.7%
US 252,185,000 207,215,000 +21.7%
Cost Of Goods And Service Excluding Amortization Of Intangible Assets 47,013 57,398 -18.1%
Amortization Of Intangible Assets 24,742 60,738 -59.3%
Show Business Segments breakouts
Life Science · Operating Segments 24,742 60,738 -59.3%
Show Fair Value By Asset Class breakouts
Finite Lived Intangible Assets 24,742 60.7 +40661.1%
Finite Lived Intangible Assets · Kebilidi 894 — —
Finite Lived Intangible Assets · Sephience 8,411 — —
Finite Lived Intangible Assets · Tegsedi 3,860 — —
Finite Lived Intangible Assets · Upstaza 8,911 — —
Finite Lived Intangible Assets · Waylivra 2,666 — —
Research & Development 455,249 534,480 -14.8%
Selling, General & Administrative 347,143 300,911 +15.4%
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 -800 -4,475 +82.1%
Gain Loss On Disposition And Impairment Of Tangible Assets -9,627 750 -1383.6%
Operating Expenses 863,720 1,109,350 -22.1%
Operating Income 866,935 -302,570 +386.5%
Interest Income Expense Nonoperating Net -152,230 -166,993 +8.8%
Other Non-Operating Income (Expense) -18,086 6,544 -376.4%
Income Before Taxes 696,619 -363,119 +291.8%
Income Tax Expense (Benefit) -13,975 -176 -7840.3%
Show Business Segments breakouts
Life Science · Operating Segments -13,975 -176 -7840.3%
Net Income 682,644 -363,295 +287.9%
Show Business Segments breakouts
Life Science · Operating Segments 682,644 -363,295 +287.9%
Show Equity Components breakouts
Retained Earnings 682,644 -363,295 +287.9%
Wtd Avg Shares (Basic) 79,534,290 76,845,055 +3.5%
Wtd Avg Shares (Diluted) 88,311,494 76,845,055 +14.9%
EPS (Basic) 8.58 -4.73 +281.4%
EPS (Diluted) 7.78 -4.73 +264.5%
Interest Expense (FY) — — —
Show Business Segments breakouts
Life Science · Operating Segments 226,308 214,307 +5.6%
Interest Income (FY) — — —
Show Business Segments breakouts
Life Science · Operating Segments -74,078 -47,314 -56.6%
Comprehensive Income 719,031 -387,896 +285.4%
Other Comprehensive Income 36,387 -24,601 +247.9%
Show Equity Components breakouts
Accumulated Other Comprehensive Income 36,387 -24,601 +247.9%
Net Income Loss Available To Common Stockholders Basic 682,644 -363,295 +287.9%
Labor And Related Expense (FY) — — —
Show Business Segments breakouts
Life Science · Operating Segments 283,583 251,184 +12.9%

Balance Sheet

Balance Sheet
Metric FY 2025 FY 2024 YoY
Current Assets
Cash & Cash Equivalents 984,648 779,709 +26.3%
Marketable Securities (Current) 960,723 359,987 +166.9%
Receivables Net Current 181,621 158,554 +14.5%
Inventory 79,647 23,194 +243.4%
Prepaid Expenses & Other Current Assets 67,309 44,087 +52.7%
Total Current Assets 2,273,948 1,365,531 +66.5%
Non-Current Assets
Property, Plant & Equipment 55,371 60,970 -9.2%
Show Geography breakouts
Non Us 1,262 1,222 +3.3%
US 54,109 59,748 -9.4%
Goodwill 82,341 82,341 0.0%
Show Business Acquisition breakouts
Agilis 82.3 82.3 0.0%
Operating Lease Right-of-Use Assets 80,053 56,685 +41.2%
Show Real Estate And Accumulated Depreciation Description Of Property breakouts
Mountainview 26.8 — —
Deposits And Other Assets Noncurrent 18,301 20,703 -11.6%
Total Assets 2,898,767 1,705,024 +70.0%
Show Geography breakouts
Non Us 373,732 361,790 +3.3%
US 2,525,035 1,343,234 +88.0%
Intangible Assets 388,753 — —
Show Fair Value By Asset Class breakouts
Finite Lived Intangible Assets 388,753 — —
Other Assets
Intangible Assets Net Excluding Goodwill 388,753 118,794 +227.2%
Current Liabilities
Accounts Payable And Accrued Liabilities Current 381,272 304,292 +25.3%
Current Portion of Long-Term Debt 286,631 — —
Deferred Revenue (Current) 2,040 5,505 -62.9%
Operating Lease Liability Current 12,484 10,363 +20.5%
Finance Lease Liability Current 3,000 3,000 0.0%
Show Counterparty Name breakouts
MassBio 3 3 0.0%
Liability Sale Of Future Royalties Current 283,000 257,821 +9.8%
Total Current Liabilities 968,427 580,981 +66.7%
Accounts Payable 45,487 17,274 +163.3%
Non-Current Liabilities
Operating Lease Liabilities 93,583 74,947 +24.9%
Finance Lease Liability Noncurrent 3,000 15,574 -80.7%
Show Counterparty Name breakouts
MassBio 3 15.6 -80.8%
Liability Sale Of Future Royalties Noncurrent 2,025,366 1,823,955 +11.0%
Other Non-Current Liabilities 13,704 21,426 -36.0%
Total Liabilities 3,104,080 2,803,095 +10.7%
Long-Term Debt (Q) — — —
Show Debt Instrument breakouts
2026 Convertible Notes · Convertible Debt 286,631 285,412 +0.4%
Stockholders' Equity
Common Stock 80 77 +3.9%
Additional Paid-In Capital 2,748,335 2,574,611 +6.7%
Accumulated Other Comprehensive Income 10,501 -25,886 +140.6%
Retained Earnings -2,964,229 -3,646,873 +18.7%
Total Stockholders' Equity -205,313 -1,098,071 +81.3%
Show Equity Components breakouts
Accumulated Net Unrealized Investment Gain Loss 787 269 +192.6%
Accumulated Other Comprehensive Income 10,501 -25,886 +140.6%
Accumulated Translation Adjustment 9,714 -26,155 +137.1%
Additional Paid In Capital 2,748,335 2,574,611 +6.7%
Common Stock 80 77 +3.9%
Retained Earnings -2,964,229 -3,646,873 +18.7%
Total Liabilities & Equity 2,898,767 1,705,024 +70.0%

Cash Flow Statement

Cash Flow Statement
Metric FY 2025 FY 2024 YoY
Operating Activities
Depreciation & Amortization 38,815 75,663 -48.7%
Operating Lease Right Of Use Asset Amortization Expense 7,467 7,752 -3.7%
Noncash Royalty Revenue Sale Of Future Royalties -228,568 -181,507 -25.9%
Noncash Interest Expense Liability Related To Sale Of Future Royalties 215,158 207,394 +3.7%
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 -800 -4,475 +82.1%
Tangible Asset Impairment Charges 1,018 4,095 -75.1%
Gain Loss On Sale Of Property Plant Equipment 130 4,298 -97.0%
Gain Loss On Modification Of Lease -10,775 -5,464 -97.2%
Clearpoint Equity Investment Fvni Unrealized Gain Loss -5,734 -7,685 +25.4%
Show Investment Type breakouts
ClearPoint Equity Investment -5,734 -7,685 +25.4%
Clearpoint Equity Investment Fv Ni Realized Gain Loss 7,081 — —
Show Investment Type breakouts
ClearPoint Equity Investment 7,081 — —
Equity Securities Fv Ni Unrealized Gain Loss -3,960 -2,572 -54.0%
Show Investment Type breakouts
Equity Securities -3,960 -2,572 -54.0%
Gain Loss On Sale Of Other Assets 163 345 -52.8%
Deferred Income Taxes -3 -55,912 +100.0%
Accretion Amortization Of Discounts And Premiums Investments -18,022 -12,529 -43.8%
Amortization of Financing Costs 1,219 1,198 +1.8%
Show Debt Instrument breakouts
2026 Convertible Notes · Convertible Debt 1,219 1,198 +1.8%
Stock-Based Compensation 74,547 74,615 -0.1%
Foreign Currency Transaction Gain Loss Unrealized 3,380 -10,374 +132.6%
Change in Inventory -53,896 6,164 -974.4%
Change in Prepaid & Other Assets -36,818 98,763 -137.3%
Increase Decrease In Receivables -10,151 1,732 -686.1%
Increase Decrease In Deposit Other Assets 2,638 12,459 -78.8%
Increase Decrease In Accounts Payable And Accrued Liabilities 71,741 -33,322 +315.3%
Increase Decrease In Other Operating Liabilities -17,396 11,830 -247.0%
Change in Deferred Revenue -3,998 4,917 -181.3%
Increase Decrease In Contingent Consideration -4,684 -1,800 -160.2%
Net Cash from Operations 711,196 -107,688 +760.4%
Investing Activities
Capital Expenditures -8,860 -6,502 -36.3%
Proceeds From Sale Of Property Plant And Equipment 70 28,056 -99.8%
Purchases of Investments -1,363,530 -607,984 -124.3%
Payments To Acquire Marketable Securities -53,628 -59,377 +9.7%
Show Investment Type breakouts
Equity Securities -53,628 -59,377 +9.7%
Proceeds From Sale Of Available For Sale Securities Debt 783,896 549,609 +42.6%
Proceeds From Sale And Maturity Of Marketable Securities 58,808 48,127 +22.2%
Show Investment Type breakouts
Equity Securities 58,808 48,127 +22.2%
Proceeds From Sale And Maturity Of Clearpoint Equity Investment 12,412 — —
Show Investment Type breakouts
ClearPoint Equity Investment 12,412 — —
Payments To Acquire Intangible Assets -291,152 -67,747 -329.8%
Net Cash from Investing -861,984 44,182 -2051.0%
Financing Activities
Proceeds From Stock Options Exercised 93,102 28,565 +225.9%
Proceeds From Stock Plans 5,944 5,199 +14.3%
Proceeds From Sale Of Future Royalties 240,000 241,792 -0.7%
Payment For Contingent Consideration Liability Financing Activities -6,341 -18,200 +65.2%
Payment Of Finance Lease Principal -1,611 -1,490 -8.1%
Net Cash from Financing 331,094 255,866 +29.4%
Supplemental
Interest Paid 5,702 5,823 -2.1%
Income Taxes Paid 36,854 17,550 +110.0%
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent 518 -57 +1008.8%
Right Of Use Asset Obtained In Exchange For Operating Lease Liability 27,675 6,462 +328.3%
Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 1,367 420 +225.5%
Noncash Or Part Noncash Fixed Assets Tenant Improvement Allowance 766 18,848 -95.9%
Milestone Payable 416 11,025 -96.2%
Unpaid Capital Expenditures 126 70 +80.0%
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations 22,712 -7,328 +409.9%
Net Change in Cash 203,018 185,032 +9.7%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 998,334 795,316 +25.5%
Income Tax Paid Federal After Refund Received 26,640 — —
Income Tax Paid State And Local After Refund Received (FY) — — —
Show Income Tax Authority breakouts
IL 4,376 — —
State And Local Tax Jurisdiction Other 854 — —
Income Tax Paid Foreign After Refund Received (FY) — — —
Show Income Tax Authority breakouts
BR 3,143 — —
Foreign Tax Jurisdiction Other 1,841 — —

Values in thousands USD. Source: SEC EDGAR 10-K filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key